Formal consensus study on surgery to replace the aortic valve in adults aged 18-60 years.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
15 05 2023
Historique:
received: 29 08 2022
accepted: 12 12 2022
medline: 17 5 2023
pubmed: 28 2 2023
entrez: 27 2 2023
Statut: epublish

Résumé

There is uncertainty about surgical procedures for adult patients aged 18-60 years undergoing aortic valve replacement (AVR). Options include conventional AVR (mechanical, mAVR; tissue, tAVR), the pulmonary autograft (Ross) and aortic valve neocuspidisation (Ozaki). Transcatheter treatment may be an option for selected patients. We used formal consensus methodology to make recommendations about the suitability of each procedure. A working group, supported by a patient advisory group, developed a list of clinical scenarios across seven domains (anatomy, presentation, cardiac/non-cardiac comorbidities, concurrent treatments, lifestyle, preferences). A consensus group of 12 clinicians rated the appropriateness of each surgical procedure for each scenario on a 9-point Likert scale on two separate occasions (before and after a 1-day meeting). There was a consensus that each procedure was appropriate (A) or inappropriate (I) for all clinical scenarios as follows: mAVR: total 76% (57% A, 19% I); tAVR: total 68% (68% A, 0% I); Ross: total 66% (39% A, 27% I); Ozaki: total 31% (3% A, 28% I). The remainder of percentages to 100% reflects the degree of uncertainty. There was a consensus that transcatheter aortic valve implantation is appropriate for 5 of 68 (7%) of all clinical scenarios (including frailty, prohibitive surgical risk and very limited life span). Evidence-based expert opinion emerging from a formal consensus process indicates that besides conventional AVR options, there is a high degree of certainty about the suitability of the Ross procedure in patients aged 18-60 years. Future clinical guidelines should include the option of the Ross procedure in aortic prosthetic valve selection.

Identifiants

pubmed: 36849232
pii: heartjnl-2022-321740
doi: 10.1136/heartjnl-2022-321740
pmc: PMC10314052
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

857-865

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: SS received speaker honoraria from Admedus. VD is a member of Heart’s editorial board.

Références

Open Heart. 2019 May 22;6(1):e001047
pubmed: 31275578
Eur J Cardiothorac Surg. 2019 Feb 1;55(2):247-255
pubmed: 30084899
Circulation. 2016 Jun 21;133(25):2662-70
pubmed: 27324361
Lancet. 2014 Aug 16;384(9943):559-560
pubmed: 25131967
J Am Coll Cardiol. 2018 Dec 4;72(22):2761-2777
pubmed: 30497563
BMJ Open. 2021 Sep 16;11(9):e046198
pubmed: 34531204
Circulation. 2021 Feb 2;143(5):e35-e71
pubmed: 33332149
Eur J Cardiothorac Surg. 2021 Oct 22;60(4):727-800
pubmed: 34453161
Eur J Cardiothorac Surg. 2021 Jul 14;60(1):34-46
pubmed: 33517391
Eur Heart J. 2019 Oct 7;40(38):3143-3153
pubmed: 31329852
Eur J Cardiothorac Surg. 2016 Jan;49(1):212-8
pubmed: 25666469
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Front Surg. 2018 Mar 02;5:18
pubmed: 29564333
J Thorac Cardiovasc Surg. 2018 Jun;155(6):2379-2387
pubmed: 29567131
Circulation. 2009 Sep 15;120(11 Suppl):S146-54
pubmed: 19752360
Circ Cardiovasc Qual Outcomes. 2018 Dec;11(12):e004748
pubmed: 30562065
Lancet. 2010 Aug 14;376(9740):524-31
pubmed: 20684981
J Thorac Cardiovasc Surg. 2020 Jun;159(6):2369-2378
pubmed: 31864692
Circ Cardiovasc Qual Outcomes. 2019 Feb;12(2):e005481
pubmed: 30760011
Eur Heart J. 2017 Dec 01;38(45):3370-3377
pubmed: 29045647
JAMA Cardiol. 2018 Oct 1;3(10):978-987
pubmed: 30326489
J Thorac Cardiovasc Surg. 2014 Sep;148(3):934-8
pubmed: 24954174
BMJ. 2011 May 26;342:d2466
pubmed: 21622509
Am J Cardiol. 2018 Jul 15;122(2):279-283
pubmed: 29880287

Auteurs

Serban Stoica (S)

Cardiothoracic Surgery, Bristol Heart Institute, Bristol, UK serban.stoica@uhbw.nhs.uk.

Chloe Beard (C)

Cardiothoracic Surgery, Bristol Heart Institute, Bristol, UK.

Johanna J M Takkenberg (JJM)

Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.

Mostafa M Mokhles (MM)

Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.

Mark Turner (M)

Department of Cardiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

John Pepper (J)

Surgery, Royal Brompton Hospital, London, UK.

Noreen Hopewell-Kelly (N)

Health and Social Sciences, University of the West of England-Frenchay Campus, Bristol, UK.

Umberto Benedetto (U)

School of Clinical Sciences, University of Bristol, Bristol, UK.

Samer A M Nashef (SAM)

Cardiac Surgery, Papworth Hospital NHS Foundation Trust, Cambridge, UK.

Ismail El-Hamamsy (I)

Mount Sinai Hospital, Los Angeles, California, USA.

Peter Skillington (P)

The Royal Melbourne Hospital, Parkville, Victoria, Australia.

Mattia Glauber (M)

Istituto Clinico Sant'Ambrogio, Milan, Italy.

Ruggero De Paulis (R)

European Hospital, Rome, Italy.

Elaine Tseng (E)

University of California San Francisco School of Medicine, San Francisco, California, USA.

Bart Meuris (B)

Cardiac Surgery, KU Leuven University Hospitals Leuven, Leuven, Belgium.

Marta Sitges (M)

Cardiology, Hospital Clinic de Barcelona, Barcelona, Spain.

Victoria Delgado (V)

Cardiology, Hospital Clinic de Barcelona, Barcelona, Spain.

Markus Krane (M)

Yale School of Medicine, New Haven, Connecticut, USA.

Martin Kostolny (M)

Cardiothoracic Unit, Great Ormond Street Hospital and Institute of Cardiovascular Science, University College London, London, UK.

Maria Pufulete (M)

Bristol Heart Institute, Bristol Medical School, University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH